Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please email your request to media@bms.com and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts

updated March 2022

Chief Executive Officer:
Headquarters:
New York City
Business:
Biopharmaceuticals
Web Address:
NYSE Listing:
BMY
Total Revenues:
$46.4 billion in 2021
R&D Investment:
$11.4 billion in 2021, which included the discovery and development of new medicines for patients
2021 Worldwide Revenues:

REVLIMID® (lenalidomide), $12.8 billion

ELIQUIS® (apixaban), $10.8 billion

OPDIVO®(nivolumab), $7.5 billion

POMALYST® / Imnovid® (pomalidomide), $3.3 billion

ORENCIA® (abatacept), $3.3 billion

SPRYCEL® (dasatinib), $2.1 billion

YERVOY® (ipilimumab), $2.0 billion

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $1.2 billion

REBLOZYL® (luspatercept-aamt), $551 million

EMPLICITI® (elotuzumab), $334 million

ABECMA® (idecabtagene vicleucel), $164 million

ZEPOSIA® (ozanimod), $134 million

BREYANZI® (lisocabtagene maraleucel), $87 million

INREBIC® (fedratinib), $74 million

ONUREG® (azacitidine tablets), $73 million

Mature and other brands* $1.9B 

*Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.

Please click on the product links to see the Full Prescribing Information for ABECMA®ABRAXANE®, BREYANZI®ELIQUIS®, EMPLICITI®, INREBIC®, ONUREG®OPDIVO®, ORENCIA®, POMALYST®, REBLOZYL®REVLIMID®SPRYCEL®, YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABECMA®ABRAXANE®BREYANZI®ELIQUIS®INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol Myers Squibb Corporate B-roll

Overview B-roll

This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.


Usage Rights & Restrictions: These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.

Scientific Media Resources >
Disease State Infographics >